Search / Trial NCT06221644

Synapse Alterations in MSA Patients

Launched by XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Jan 15, 2024

Trial Information

Current as of October 03, 2024

Completed

Keywords

Synaptic Density; Pet; Sv2 A

Description

60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment. Visual, voxel, and volumetric region-of-interest (VOI) analyses were employed to elucidate synaptic density patterns in the MSA brain and establish visual diagnostic criteria. VOI-based computer-assisted analyses were utilized to develop diagnostic models for MSA.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • The MSA patient were diagnosed according to the 2008 Second Consensus Criteria and confirmed by two experienced neurologists.
  • Exclusion Criteria:
  • encompassed MRI contraindications, a history of epilepsy, stroke, or brain surgery, intracranial organic lesions unrelated to MSA, usage of levetiracetam or brivaracetam, and a history of alcohol or drug abuse

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Changsha, Hunan, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0